Voriconazole-Induced Photosensitivity

  1. David M. Aronoff, MD
  1. Anurag N. Malani, MD, Division of Infectious Diseases and the Department of Internal Medicine St. Joseph Mercy Hospital Ann Arbor, Michigan and Division of Infectious Diseases and the Department of Internal Medicine University of Michigan Health System Ann Arbor, Michigan
  2. David M. Aronoff, MD, Division of Infectious Diseases and the Department of Internal Medicine University of Michigan Health System Ann Arbor, Michigan
  1. Reprint Requests:
    Anurag N. Malani, M.D., Division of Infectious Diseases, St. Joseph Mercy Hospital, 5333 McAuley Dr Suite 3106, Ypsilanti, MI 48197, Tel: 734-712-8600, Fax: 734-712-8636, Email: malanian{at}umich.edu

Abstract

Voriconazole is a broad-spectrum triazole antifungal agent indicated for invasive aspergillosis, refractory Candida infections, and other emerging invasive fungal infections. Adverse cutaneous reactions associated with voriconazole therapy occur in fewer than 10% of treated patients and range from mild erythematous eruptions to life-threatening reactions such as the Stevens-Johnson syndrome and toxic epidermal necrolysis. Photosensitivity reactions are an uncommon but characteristic dermatitis in voriconazole recipients, particularly following chronic administration. We report a case of voriconazole-induced phototoxicity in a 50-year-old male with Candida parapsilosis endocarditis that reversed on discontinuation of the drug.

| Table of Contents